Please tell us about your clinical experience. How many patients do you treat with Severe Hypertriglyceridemia or Dyslipidemia? What is currently the most efficient treatment in each indication ?

What’s unique about Arrowhead’s approach to cardiometabolic conditions?Can you tell us more about how targeting angiopoietin like protein 3 (ANGPTL3) works in treating dyslipidemias? Please also tell us about the mechanism of action of targeting apolipoprotein C-III (APOC3) for severe hypertriglyceridemia.

What are your thoughts on the once every 4 months to once every 6 months dosing regimen? How convincing is the the long duration of effect of ARO-APOC3 and ARO-ANG3 to you? Can you name some other agents and mechanisms that require more frequent dosing? Would you give up on those and switch to Arrowhead’s treatment option?

Even though there has been no drug-related discontinuations, common adverse events included headache and respiratory tract infections. How problematic is the latter one from your point of view?

Mean maximum reductions in APOC3 at 50 mg dose was recently reported at 97% in phase ½a. Mean maximum reductions in triglycerides stood at 95% and mean maximum absolute reduction in TG: -3183 mg/dL.
How do you comment on those data points? How satisfactory are the results, comparable to what you’re used to seeing in practice?

• In Hypercholesterolemia patients on a stable LDL-C lowering treatment regimen including statins, with or without ezetimibe, and some receiving PCSK9 inhibitors, mean maximum reductions in ANGPTL3 of 79-88% and mean maximum reductions in LDL-C of 39-42%.were reported.
• Hypertriglyceridemia results were: mean maximum reductions in ANGPTL3 of 83%v+ Mean maximum reductions in TG of 79%